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Abstract
Background: Bacteriocins are antimicrobial peptides that are produced by bacteria as a defense mechanism in complex
environments. Identification and characterization of novel bacteriocins in novel strains of bacteria is one of the important
fields in bacteriology.
Methodology/Findings: The strain GI-9 was identified as Brevibacillus sp. by 16 S rRNA gene sequence analysis. The
bacteriocin produced by strain GI-9, namely, laterosporulin was purified from supernatant of the culture grown under
optimal conditions using hydrophobic interaction chromatography and reverse-phase HPLC. The bacteriocin was active
against a wide range of Gram-positive and Gram-negative bacteria. MALDI-TOF experiments determined the precise
molecular mass of the peptide to be of 5.6 kDa and N-terminal sequencing of the thermo-stable peptide revealed low
similarity with existing antimicrobial peptides. The putative open reading frame (ORF) encoding laterosporulin and its
surrounding genomic region was fished out from the draft genome sequence of GI-9. Sequence analysis of the putative
bacteriocin gene did not show significant similarity to any reported bacteriocin producing genes in database.
Conclusions: We have identified a bacteriocin producing strain GI-9, belonging to the genus Brevibacillus sp. Biochemical
and genomic characterization of laterosporulin suggests it as a novel bacteriocin with broad spectrum antibacterial activity.
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Introduction
Bacteriocins are ribosomally synthesized antimicrobial peptides
and have drawn attention in recent years due to their potential
therapeutic applications in treating bacteria, including multiple
drug resistant bacteria [1–3]. Bacteriocins from lactic acid bacteria
have been in use for a while as natural preservatives in food
industry [4,5]. Although bacteriocins were originally found to be
produced by Lactobacillus only, it was subsequently shown to be
produced by different species and multiple strains. Consistent with
this, many species belonging to the genus Bacillus as well as other
Gram-positive and Gram-negative bacteria were shown to
produce bacteriocins and/or bacteriocin-like substances [6]. In
fact, it is observed that majority lineages of bacteria are shown to
produce at least one bacteriocin as part of their defense
mechanism [7,8]. Likewise many species belonging to the genus
Bacillus were reported to produce bacteriocins and/or bacteriocin
like substances [9–11].
Antimicrobial peptides produced by bacteria are categorized
into different classes based on structural and functional
characteristics [12]. The class I bacteriocins called as lantibiotics,
are well studied with wide applications in both therapeutic and
preservation of food products at industrial scale [1,13,14]. Class
II bacteriocins are further divided into different sub classes,
including antilisterial one-peptide pediocin like bacteriocin as
sub-class IIa [15–18], the two-peptide bacteriocins as sub-class
IIb [14,17–19], sub-class IIc containing cyclic bacteriocins and
sub-class IId composed of one-peptide non-cyclic bacteriocins
that show no sequence similarity to other bacteriocins [14,17,20].
Among these different classes of bacteriocins, lantibiotics are
found to undergo post translational modifications such as
dehydration of Ser and Thr to produce dehydroalanine (Dha)
and dehydrobutyrine (Dhb) respectively. The lantibiotics are
further divided into two groups based on their structure as group
A contains globular lantibioitics and group B composed of linear
lantibiotics. Both groups were also found to differ in their
mechanism of inhibition activity. Most of the bacteriocins
produced by Bacillus spp. belong to the class I lantibiotics and
exhibit broad range molecular mass, from smallest lichenin
(1.3 kDa) produced by B. licheniformis [21] to largest thuricin
(950 kDa) produced by B. thuringiensis [22]. Moreover, they were
found to be active at relatively high temperatures and over a wide
pH range [23] with potential for therapeutic as well as industrial
applications. For example, mersacidin is one such bacteriocin
produced by Bacillus sp., which inhibits the growth of methicillin
resistant Staphylococcus aureus [24].
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are shown to produce different bacteriocins, the antimicrobial sub-
stances produced by few Brevibacillus taxa have not been characterized
in detail. Furthermore, B. brevis [25,26] and B. laterosporus [27] have
been shown to produce bacteriocin-like inhibitory substances (BLIS)
with wide pH and temperature stability. Other than these, B.
laterosporus strain SA14 was shown to produce two antibiotics [28]. In
the present study, we describe the isolation, purification and
characterization of a bacteriocin produced by Brevibacillus sp. strain
GI-9 exhibiting broad spectrum antibacterial activity.
Results
Phenotypic characterization
Most of the strains isolated from subsurface soil sample with
antimicrobial activity were found to be facultative anaerobes (see
Methods). Among these, a strain designated as GI-9, exhibited
broad spectrum antibacterial activity by inhibiting the growth of B.
subtilis (MTCC 121), S. aureus (MTCC 1430), E. coli (MTCC 1610),
P. aeruginosa (MTCC 1934) and L. monocytogenes (MTCC 839).
Phenotypic properties and 16 S rRNA gene sequence (EMBL
accession No. FR686596) BLAST analysis of the strain GI-9
assigned it to the genus Brevibacillus. It had high percent identity
(99%) of the strain GI-9 16 S rRNA gene to that of B. laterosporus
DSM 25 and showed less than 97% with other species of the
genus. However, it showed differences in phenotypic properties
such as growth at 50uC, positive reaction for Voges Proskauer test
and urea hydrolysis compared to B. laterosporus DSM 25.
Antibacterial activity assay
Cell-free fermented broth (CFB) collected at indicated time
intervals during growth of strain GI-9 were used to perform
antimicrobial activity assays. The results showed that bacteriocin
production initiated after 12 hours of lag phase. However, there
was a significant increase in bacteriocin production between 13 to
18 hours (Fig. 1) and the antimicrobial activity remained constant
thereafter as measured by inhibition zone. Although it displayed a
broad-spectrum antibacterial activity, it did not show any growth
inhibition against yeast or fungi. Notably, the medium composi-
tion did not influence antimicrobial activity of the bacteriocin as
similar results were obtained when GI-9 was grown in minimal
medium and subsequently assayed for antimicrobial activity. The
growth inhibition studies showed that test strains B. subtilis and S.
aureus were more sensitive than other strains.
Purification of laterosporulin
The CFB obtained after 48 hours growth was tested for
antimicrobial activity. The bacteriocin present in CFB was
extracted by affinity chromatography using Diaion HP-20 and
purified by a combination of chromatographic techniques. To
remove large proteins, the crude extract was passed through a
30 kDa protein concentrator. The filtrate obtained was found to
exhibit antimicrobial activity and the same was applied on to gel
filtration columns for purification. The predominant peak shown
in Fig. 2A exhibited antimicrobial activity on test strains. Re-
injection of this predominant peak gave only one peak at the same
retention time suggesting that the minor peaks observed in the
previous chromatogram were not degradation products of the
antimicrobial peptide. Based on the elution profile of standards,
the peak with antimicrobial activity may have mass in the range of
5.3 to 10.1 kDa. This peptide was finally purified on a semi-
preparative reversed-phase-HPLC. The purified peptide showed a
single peak at UV absorption of 220 nm and was positive for
antimicrobial activity. Tricine-SDS-PAGE analysis of this peptide
Figure 1. Comparison of bacteriocin production at different phases of growth curve. The growth curve analysis of strain Brevibacillus sp.
GI-9 indicates that the production of bacteriocin initiated at late logarithmic phase. Growth measured as absorption at 600 nm is indicated by
squares (left y axes), while the bacteriocin activity by triangles (right y axes).
doi:10.1371/journal.pone.0031498.g001
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molecular mass and N-terminal sequencing.
Determination of molecular mass and N-terminal
sequence analysis
The molecular mass observed for laterosporulin by MALDI-
TOF was 5605.8 Da (Fig. 3), which is in good agreement with
mass obtained by gel filtration chromatography (Fig. 2A). The N-
terminal sequence of laterosporulin yielded partial sequence of
1A(M)Q(C)QG(C/Q)PDAISGWTHTDYQCH
19 for two inde-
pendently processed samples. The uncertainties at the 1
st,2
nd
and 4
th positions obtained in N-terminal sequences were
considered to predict the antibacterial activity of each possible
peptide sequence using a database of peptides with known
antimicrobial potency. Notably, one of the peptides (ACQCP-
DAISGWTHTDYQCH) predicted highest relative activity com-
pared to other combinations. To confirm the antimicrobial activity
of this partial peptide, it was custom synthesized, mass was
Figure 2. Gel filtration elution profile of laterosporulin (A) and analysis (B). (A) The major peak (highlighted fraction) in gel filtration
chromatography shows antimicrobial activity and the calibration curve obtained from protein standards indicates mass of the peptide in the range of
5.3 to 10.1 kDa. (B) Tricine-SDS-PAGE analysis of the major peak showed a single band; lane 1, molecular weight markers; lane 2, purified
laterosporulin.
doi:10.1371/journal.pone.0031498.g002
Figure 3. MALDI-TOF mass spectrometry analysis of laterosporulin. The purified bacteriocin from Brevibacillus sp. GI-9 shows the mass (m/z)
of 5.6 kDa.
doi:10.1371/journal.pone.0031498.g003
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examined in growth inhibition assays using indicator strains B.
subtilis and E. coli. The peptide exhibited weak antimicrobial
activity at significantly higher concentration. Upon extensive
bioinformatic analysis, no significant similarity was observed to
this partial sequence with available bacteriocins in the databases
like BACTIBASE or Antimicrobial Peptide database. Also, careful
inspection of peptide mass fingerprinting (PMF) data using the
databases such as MASCOT and PROWL revealed no similarity
with any antimicrobial peptides.
Minimum inhibitory concentration analysis
This was confirmed by MIC (minimum inhibitory concentra-
tion) analysis, where above strains were found to be inhibited at
lower MIC values compared to other test strains (Fig. 4). To gain
insight into the mode of bactericidal action of the laterosporulin on
indicator strain, we performed scanning electron microscopy
(SEM) of E. coli treated with lethal dose of bacteriocin. When
compared to untreated bacteria, E. coli cells pre-incubated with
500 mg/ml of purified peptide for 4 hours displayed significant
modifications in cell shape and morphology (Fig. 5). The
modifications included roughening of the cell surface with
accumulation of cell debris and lysis of bacteria.
Temperature, pH stability and resistance to proteolytic
enzymes
The results of heat stability assay for laterosporulin confirmed
that the bacteriocin was fully heat stable as there was no reduction
in antimicrobial activity even after exposing it to 120uC for
15 min. It was also found to be stable under a wide range of pH as
there was no reduction in antimicrobial activity observed between
2.0 to 10.0. However, the antimicrobial activity of laterosporulin
was reduced significantly above pH 10. The antimicrobial assay
performed upon incubation of laterosporulin with proteolytic
enzymes (pepsin, trypsin, chymotrypsin, proteinase K, pronase E)
did not show any reduction in its antimicrobial activity. Further,
no reduction in antimicrobial activity upon treatment of
laterosporulin with amylase indicates the absence of any sugar
moiety associated with antimicrobial activity.
Analysis of the laterosporulin encoding gene cluster
To identify the ORF that encodes the laterosporulin, we
identified a 4 kb region from the preliminary draft genome of GI9
(unpublished). We further confirmed the 4 kb region (HE579167)
by re-sequencing (see Methods). Genomic organization of the 4 kb
region that contains the putative structural gene encoding
laterosporulin and its flanking genes is schematically shown in
Fig. 6A. The predicted ORF of 153 nucleotides following the
putative Shine-Dalgarno sequence (Fig. 6B) most likely codes for
the antimicrobial peptide. In agreement with this, the deduced
amino acid sequence (of the ORF) fully matches with the partial
N-terminal sequence of the peptide. However, the homology
searches revealed that the ORF predicted is novel to our species
and there is no similar or identical homolog has been identified in
any other species of bacteria. Recently genome sequence of
another strain (LMG 15441) identified as Brevibacillus laterosporus
has been submitted in NCBI (GenBank accession No
AFRV01000005). Like in our strain, all the 4 kb sequence is also
present in the genome of this strain and shows 98.3% nucleotide
identity. Even though the genomic region is present in this strain,
the putative ORF that encodes the laterosporulin is not annotated
and missed by their annotation pipeline (although it is encoded in
the genome and is 100% identical at nucleotide sequence). The
region on the right side of this ORF is flanked by a putative
transcriptional regulator gene and on its left side by three putative
genes that encode a hypothetical protein, ABC transporter protein
and a dehydrogenase gene. The list of predicted ORFs and their
most similar homologs is given in Table S1. The transcriptional
orientation of all ORFs is in the same direction (Fig. 6a) and the
G+C content of this 4 kb region is only 36.6 mol%, which is
somewhat lower than the average G+C content of the genome of
Brevibacillus sp. strain GI-9 estimated to be 41 mol%.
Discussion
Members of the genus Bacillus are well known to produce
bacteriocins, largely classified as lantibiotics with many placed
within the class II bacteriocins [15,19]. Apart from Bacillus, genus
Paenibacillus is also known to produce antimicrobial substances
such as polymixins. However, species belonging to other genera
like Brevibacillus and Geobacillus are sparsely explored for antimi-
crobials [25–29]. Thus, exploration of these genera and other close
relatives for antimicrobials may result in isolation of novel
bacteriocins for various applications, in addition to increasing
the knowledge in this field. This study provides the first
characterization of a bacteriocin produced by Brevibacillus sp.
strain GI-9 with activity against a diverse range of bacteria. The
most essential parameter for characterization of a bacteriocin is
obtaining it in a pure form using different chromatographic
techniques [30,31] including size exclusion and affinity chroma-
tography [32–36] after ammonium sulfate precipitation. The
purification of laterosporulin involved extraction from a 48 hour
culture supernatant using Diaion HP-20 resins, followed by
filtration chromatography and reversed-phase high performance
liquid chromatography. As an alternative to the ammonium sulfate
precipitation few studies reported utilization of hydrophobic
interaction of resins to extract selective peptides [20,37]. Our
results clearly suggest that the utilization of Diaion HP-20 could
result in high yield and subsequent additional chromatography
resulted in obtaining the pure compound.
The purified laterosporulin showed a single band on Tricine-
SDS-PAGE, the molecular mass analysis of this peptide using
calibration curve obtained from gel filtration chromatography and
MALDI-TOF revealed low molecular weight which is generally
Figure 4. Determination of MIC for laterosporulin produced by
strain GI-9. The MIC assay for Gram-positive and Gram-negative
bacteria with purified laterosporulin using micro-titer plates in
triplicates revealed that B.subtilis and S. aureus are highly sensitive.
doi:10.1371/journal.pone.0031498.g004
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gel filtration chromatography could be due to conformational
polydispersity which is not too uncommon for peptides. To
ascertain the molecular mass with higher reliability, we carried out
MALDI-TOF of the active peak which gave a mass of 5.6 kDa. In
fact, the molecular weight of intact peptide obtained by gene
sequence slightly differed with the mass obtained by MALDI-
TOF. We speculate that this is a result of peptide maturation
where the N-terminal extension of precursor peptide is cleaved off
by the action of an enzyme like Met aminopeptidase (MAP) that
cleaves at a Met residue when the adjacent residue is a nonbulky
amino acid [38]. However, unlike the class II bacteriocins or some
of the class I lantibiotics where maturation proteases are associated
with an ABC transporter gene [39], strain GI-9 do not contain any
significant N-terminal protease domain in ABC transporter.
Nonetheless, four copies of genes exhibiting similarity with the
Figure 5. Bactericidal effect of laterosporulin on E. coli. The scanning electron micrographs of E. coli cells without laterosporulin treatment (A)
and after laterosporulin treatment (500 mg/ml) for 4 h (B). Note that the treatment of E. coli displaying roughening of cell surface with cell debris as a
result of treatment.
doi:10.1371/journal.pone.0031498.g005
Figure 6. Genetic organization of 4 kb region of the genome encoding laterosporulin (A) and nucleotide sequence of the ORF (B).
The putative ORF encoding laterosporulin structural gene is shown by filled arrow and flanking ORFs as shown by empty arrows (A). Panel B shows
the nucleotide sequence of the laterosporulin gene (encoding the indicated amino acids) with putative start codan, stop codons and ribosome
binding site (RBS) shown in bold.
doi:10.1371/journal.pone.0031498.g006
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maturation of peptide is also noticeable from the repeated N-
terminal sequences of the peptide which yielded Ala as the first
amino acid. The theoretical mass calculated for the peptide
obtained from gene sequence upon maturation of peptide
(5619.3 Da) is still 13.5 Da higher than the experimental mass
observed. However, Gaussian fit to the single peak observed in
MALDI-TOF experiment suggested that the peptide molecules
have a flight time corresponding to mass of 5605.8 633.6 Da and
this range covers the theoretical mass of the peptide. Low similarity
of the laterosporulin amino acid sequence with existing bacteriocins
suggests that it could be a novel bacteriocin. Moreover, the
continuous N-terminal sequence obtained in the present study
revealed the absence of modified amino acids likedehydrated Ser or
Thr which are formed as a result of post-translational modifications.
In addition to this, treatment of peptide with dithiothreitol (DTT),
used to disrupt disulfide bonds, did not affect laterosporulin’s
antimicrobial activity or result in any migration differences on SDS-
PAGE (data not shown). Further, the bacteriocin is neither
composed of two peptides nor contain YGNGVXC motif at N-
terminus, which is observed in anti-listerial pediocine like
bacteriocins. Interestingly, though laterosporulin did not show the
YGNGVXC motif, it could inhibit the growth of test strain L.
monocytogenes, supporting the hypothesisthat YGNGVXC motif does
not play any role in inhibiting the growth of Listeria [40]. These
severallinesof evidence suggest that the antimicrobial peptide inthe
present study belongs to a novel heat stable class II bacteriocin
family [41]. In addition to this, the PMF analysis of the
antimicrobial peptide using MASCOT and PROWL database
analyses revealed no significant similarity with any of the known
bacteriocins or antimicrobial peptides produced by bacteria. This
was in agreement with the BLAST analysis of a partial N-terminal
amino acid sequence against the GenBank protein database and an
antimicrobial peptide database that did not reveal any similarity
with known antimicrobial peptides. Interestingly, the partial N-
terminal sequence of the peptide revealed the absence of cationic
amino acids such as Lys or Arg, but it still exhibited antimicrobial
activity. Recently, another N-terminal sequence was also reported
to lack cations in its partial sequence [20].
One of the hallmarks of the ORFs that encode bacteriocins is
their small size (50–70 aa). Due to their small size, genes encoding
bacteriocins are often difficult to identify. In our case, the
availability of the purified peptide, its partial N-terminal sequence
and the draft genome of the source strain helped to identify the
putative ORF that encodes the laterosporulin, along with adjacent
genes. As expected, the putative ORF that encodes the laterospor-
ulin is only 153 bp (50 aa). The other hallmark of a genomic region
that encodes a bacteriocin is the presence of genes necessary for
regulation, transport, modification, etc. The 4 kb region encodes
such genes and the fact that transcriptional orientation of all these
genes is in same direction suggests that they are part of a genetic
cassette responsible for laterosporulin production (Fig. 6A). Even
though bacteriocins are known to be strain specific, the presence of
an ORF with significant similarity to the putative laterosporulin-
encoding ORF in the genome of Brevibacillus laterosporus strain
LMG15441 [42] suggests that this strain may produce a related
bacteriocin. This highlights the importance of conducting a
functional screen to identify bacteriocins.
Many antibiotics are already in use to combat disease or to
avoid the food spoilage. Consequently, increased use of these
antibiotics resulted in multiple antibiotic resistance in pathogens
and food spoiling bacteria. Thus, it is essential to discover novel
antimicrobial substances to combat these drug resistant bacteria.
The properties such as thermo-stability, pH tolerance and
resistance to proteolytic enzymes observed for bacteriocins has
fostered their therapeutic and food preservation applications. In
this study, laterosporulin was found to be thermo stable, pH
tolerant and resistant to proteolytic enzymes. These properties of
laterosporulin can increase the potential applications of the
bacteriocin alone or in combination with other bacteriocins.
Materials and Methods
Isolation and growth media
The bacterial strain GI-9 was isolated from a subsurface
farmland soil sample in Chandigarh, located in northern part of
India. No specific permissions were required for sample collection
as the location is with in the institute’s campus and the study did
not involve any recombinant materials. The sample was collected
and immediately transferred to laboratory for processing. It was
serially diluted and plated onto tryptone soya agar (TSA) medium
with the following composition (g/l) pancreatic digest of casein,
15.0; papaic digest of soybean meal, 5.0; sodium chloride, 5.0;
agar 15.0 and the pH adjusted to 7.2. The plates were incubated
for 4 days at 30uC under anaerobic conditions. Colonies with
inhibition zones were isolated, purified and preserved at 270uC
for further studies. All test strains in the present study were
procured from Microbial Type Culture Collection (MTCC),
Chandigarh, India and grown on TSA.
Bacterial identification
Morphological characteristics of cell and spore were observed
under phase contrast microscope (Zeiss, Axiophot). Physiological
tests like growth at different temperature and pH were determined
using TSA as basal medium. Other biochemical tests were
performed according to the standard procedures [43,44]. PCR
amplification of the 16 S rRNA gene was done using universal
primers 8-27f (59-AGAGTTTGATCCTGGCTCAG-39) and
1492r (59-TACGGYTACCTTGTTACGACTT-39). Amplified
PCR product was purified and sequenced as described [45].
Almost complete sequence of 16 S rRNA gene (submitted to
EMBL under the accession No.FR686596) was used for BLAST
search using NCBI and EZ Taxon servers.
Determination of bacteriocin activity
The CFB of strain GI-9 was used to determine the antimicrobial
activity. Culture was grown for 48 hours in nutrient broth (NB,
Himedia) and subsequently cells were removed by centrifugation
(10,000 rpm for 10 min, 4uC). The supernatant obtained was
filtered by using 0.22 mm filter (Millipore). The filtrate was diluted
by two fold dilution and amounts of 100 ml of different dilutions
were used to test the activity. These dilutions were added to the
wells that are prepared in plates containing nutrient agar medium
seeded with test organism. Above test was also performed using
minimal medium to check influence of the medium components
on antimicrobial activity. A growth curve up to 24 hours was
prepared for strain GI-9 to examine the bacteriocin production at
different stages. One unit of bacteriocin was defined as the lowest
dilution that was given an inhibition zone around the well and
reciprocal of this dilution is defined as the unit of antimicrobial
activity per ml.
Bacteriocin production and purification
An isolated colony was used to inoculate 50 ml of NB medium
and incubated at 30uC with shaking at 120 rpm for 24 hours. This
culture was used to inoculate 1 liter flasks containing 500 ml of
NB. The culture was grown for 48 hours at 30uC and subsequently
cells were separated by centrifugation (10,000 g, 15 min at 4uC).
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(Supelco) resin and the bacteriocin was eluted with methanol as
described [35]. Methanol was evaporated using a rota vapor
(BUCHI Rota vapor R-200) and the dried peptide content was
dissolved in Milli-Q water. This crude extract was passed through a
30 kDa protein concentrator (Millipore, USA) and the active
fraction obtained was applied onto a manually packed and
calibratedsephacryl HR-100 column 16/66 (GEHealthcare) linked
to an AKTA prime plus (GE Healthcare). The elution was done in
50 mM sodium phosphate buffer (pH 7.2) containing 50 mM NaCl
at flow rate of 0.5 ml/min and monitored through UV detector
(220 nm). Fractions of 5 ml were precipitated through TCA and re-
dissolved in Milli Q water to test the antimicrobial activity. The
active fraction was applied onto gel filtration HPLC column
(Shodex KW-803) along with molecular weight standards insulin,
ribonucleaseA,chymotrypsinogen,ovalbumin,conalbumin,ferritin
and blue dextran. Finally the bacteriocin was applied onto reversed-
phase chromatography (Schimadzu Scientific Instruments, Japan)
and purified using semi-preparative C-18 column (Phenomenex,
Luna 5m C-18). The bacteriocin was eluted with 0–100% linear
gradient of acetonitrile containing 0.1% trifloroacetic acid (TFA)
with a flow rate of 0.5 ml/min. The purified bacteriocin was
collected, lyophilized and re-dissolved in water to appropriate
concentration. It was used to test antimicrobial activity and applied
on Tricine-SDS-PAGE (16.5%).
Determination of minimum inhibitory concentration
The MIC of bacteriocin for different strains was evaluated by
using a microtiter plate dilution assay. Test strains were grown to
logarithmic phase under optimal conditions (up to 0.3 OD) and the
test was performed in triplicates. Each well of the microtiter plate
was added with 200 ml of fresh nutrient medium and 50 ml of test
strains in different rows. Subsequently, different dilutions (50 ml) of
freshly prepared bacteriocin were added to each well. The first
column of the microtiter plate was left as a blank while reading
through an ELISA plate reader (Thermo Scientific). The microtiter
plates were incubated at 30uC incubator and OD was measured at
600 nm at different time intervals. The lowest concentration that
inhibited growth of test strains and did not show any increase in
absorption after 48 h was considered as MIC.
To examine the bactericidal activity, E.coli cells were grown in
NB to an exponential phase, harvested by centrifugation. The
pellet obtained was resuspended in fresh NB and aliquots of 5 ml
containing about 2610
7 cells/ml were incubated at 37uC for
4 hours with 500 mg/ml laterosporulin. Samples at 0, 2 and
4 hours interval were centrifuged and pellets were resuspended in
500 ml of phosphate buffer. Each sample was spread on a poly (L-
lysine)-coated glass slides (18618 mm) to immobilize bacterial cells
and incubated at 30uC for 90 min. They were fixed with modified
Karnovsky’s fixative [46] and dehydrated with a graded ethanol
series. After freeze drying and platinum coating, the samples were
observed with a Zeiss EVO 40 instrument.
Effect of pH, temperature and hydrolytic enzymes on
bacteriocin activity
The sensitivity of the purified bacteriocin towards different pH,
temperature and proteases was evaluated. To determine pH and
temperature resistance, the purified peptide was incubated at
different pH values between 2.0–12.0 and temperatures 80, 100uC
for 30 min and 120uC for 15 min. Different hydrolytic enzymes
including pepsin, trypsin, chymotrypsin, proteinase K, pronase E
and amylase were incubated with bacteriocin for 6 hours at 37uC
to ensure their effect. The enzyme activity was terminated by
heating at 80uC before the bacteriocin activity was confirmed.
Intact mass analysis and peptide mass fingerprinting
For intact mass analysis of bacteriocin, 1 ml of the peptide
sample was mixed with equal amount of a-cyano-4-hydroxycin-
namic acid in 0.1% (v/v) TFA. Sample was dried and analyzed on
an ABI voyager DE STR mass spectrometer (Applied Biosystems).
The HPLC purified, functional entity was loaded on to Tricine-
SDS-PAGE, upon electrophoresis the protein band was subjected
to overnight digestion (at 37uC for about 16 hours) using trypsin
and the mass of the generated fragments were analyzed [47]. The
observed mass and their relative intensities were used to identify
the parent sequence by peptide mass fingerprinting against profiles
of known sequences using MASCOT and PROWL servers.
N-terminal amino acid sequencing and analysis
After separation by Tricine-SDS-PAGE, the peptides were
transferred on to PVDF membrane (Bio-Rad), rinsed with Milli-
Q water, stained with amido black (Sigma) for 2-3 min and
destained with several changes of 50% methanol. The membrane
was finally rinsed in Milli-Q water. The excised peptide band was
subjected to N-terminal sequencing. The N-terminal sequence
was determined by automatic degradation in Procise 491 cLC
protein sequencer (Applied Biosystems). The partial sequence
obtained was analyzed for its ability to resemble profile of
antibacterial peptide by comparing with sequences of peptides
with known potency against microbes [48] (http://aps.unmc.
edu/AP/main.php).
Peptide synthesis
To evaluate antibacterial function of the N-terminal peptide, a
19-mer peptide representing the N-terminal sequence of the
bioactive protein was synthesized using standard Fmoc-chemistry
on 2-chlorotrityl resin (0.2 mmol/g). Synthesis was carried out on
a semi-automated synthesizer (PS-II) (Protein Technologies Inc.,
AZ USA). It was cleaved with TFA and purified by RP-HPLC
system (Dionex, Ultimate-3000) using C-18 analytical column.
The purified peptide was subjected to MALDI-TOF analysis for
confirmation of molecular mass.
DNA sequence analysis
The DNA was isolated as described by Sambrook et al. [49].
TBLASTN was carried out using the laterosporulin N-terminal
sequence against the draft genome of our strain GI-9 (unpublished)
to fish out region encoding the putative structural gene for the
bacteriocin and its flanking genes. Further, this region was re-
sequenced using a set of overlapping primers (Table S2)o na n
ABI 310 Genetic Analyzer (Applied Biosystems) and annotated
using NCBI ORF finder (http://www.ncbi.nlm.nih.gov/projects/
gorf/). Homology searches were performed at NCBI (http://www.
ncbi.nlm.nih.gov/) and published bacteriocin databases such as
antimicrobial peptide database, BAGEL and BACTIBASE [50–
52]. The 4 kb sequence of laterosporulin gene cluster described in
the present study has submitted to EMBL under the accession
number HE579167.
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